Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract.
Esophageal squamous cell carcinoma
Gastric adenocarcinoma
Gastroesophageal junction adenocarcinoma
Immune checkpoint inhibitor
PD-L1 testing
Predictive biomarkers
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
10
07
2023
accepted:
11
07
2023
medline:
2
11
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area of cancers of the esophagus, gastroesophageal junction and stomach is constantly increasing. Since the treatment indication for PD-1 inhibitors that are currently approved in the European Union is often linked to the expression of PD-L1 (programmed cell death-ligand 1), the evaluation of tissue-based predictive markers by the pathologist is of crucial importance for treatment stratification. Even though the immunohistochemical analysis of the PD-L1 expression status is one of the best studied, therapy-relevant biomarkers for an immuno-oncological treatment, due to the high heterogeneity of carcinomas of the upper gastrointestinal tract, there are challenges in daily clinical diagnostic work with regard to implementation, standardization and interpretation of testing. An interdisciplinary group of experts from Germany has taken a position on relevant questions from daily pathological and clinical practice, which concern the starting material, quality-assured testing and the interpretation of pathological findings, and has developed recommendations for structured reporting.
Identifiants
pubmed: 37874352
doi: 10.1007/s00432-023-05180-5
pii: 10.1007/s00432-023-05180-5
pmc: PMC10620316
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16231-16238Informations de copyright
© 2023. The Author(s).
Références
Oncotarget. 2018 May 1;9(33):22945-22959
pubmed: 29796164
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Z Gastroenterol. 2019 Dec;57(12):1517-1632
pubmed: 31826284
Oncotarget. 2016 Apr 26;7(17):24269-83
pubmed: 27009855
J Immunother Cancer. 2016 Oct 18;4:65
pubmed: 27777774
Chin J Cancer. 2017 Jul 29;36(1):61
pubmed: 28754154
Lancet. 2021 Aug 28;398(10302):759-771
pubmed: 34454674
Cancer Cell Int. 2020 May 24;20:186
pubmed: 32489322
ESMO Open. 2021 Feb;6(1):100036
pubmed: 33460964
J Cancer. 2012;3:137-44
pubmed: 22481979
Gastric Cancer. 2019 Jan;22(1):147-154
pubmed: 29860599
J Clin Oncol. 2023 Mar 1;41(7):1470-1491
pubmed: 36603169
EBioMedicine. 2021 Jan;63:103137
pubmed: 33310681
J Clin Oncol. 2021 Apr 1;39(10):1165-1184
pubmed: 33527845
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
Clin Cancer Res. 2020 Dec 15;26(24):6453-6463
pubmed: 32820017
N Engl J Med. 2022 Feb 3;386(5):449-462
pubmed: 35108470
Curr Oncol. 2022 Mar 02;29(3):1559-1574
pubmed: 35323331
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Biol Direct. 2022 Jun 6;17(1):15
pubmed: 35668531
Nat Commun. 2019 Apr 11;10(1):1670
pubmed: 30975989
Ann Oncol. 2022 Oct;33(10):992-1004
pubmed: 35914638
Ann Oncol. 2017 May 1;28(5):912-913
pubmed: 28368465
Dtsch Arztebl Int. 2021 Apr 16;118(Forthcoming):
pubmed: 33536117
Histopathology. 2020 Sep;77(3):340-350
pubmed: 32320495
Pathologe. 2020 Dec;41(Suppl 2):76-82
pubmed: 33427920
Appl Immunohistochem Mol Morphol. 2021 Jul 1;29(6):462-466
pubmed: 33480602
Transl Oncol. 2020 Feb;13(2):165-176
pubmed: 31865179
Gut. 2020 Sep;69(9):1564-1571
pubmed: 32606208
Gastric Cancer. 2021 Sep;24(5):1115-1122
pubmed: 33954872
Jpn J Clin Oncol. 2015 May;45(5):416-21
pubmed: 25732909
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137